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BACKGROUND: The TFII-I is a multifunctional transcriptional factor known to bind specifically to several DNA sequence elements and
to mediate growth factor signalling. A microdeletion at the chromosomal location 7q11.23 encoding TFII-I and the related family of
transcription factors may result in the onset of Williams–Beuren syndrome, an autosomal dominant genetic disorder characterised by
a unique cognitive profile, diabetes, hypertension, anxiety, and craniofacial defects. Hereditary breast and ovarian cancer susceptibility
gene product BRCA1 has been shown to serve as a positive regulator of SIRT1 expression by binding to the promoter region of
SIRT1, but cross talk between BRCA1 and TFII-I has not been investigated to date.
METHODS: A physical interaction between TFII-I and BRCA1 was explored. To determine pathophysiological function of TFII-I, its role
as a transcriptional cofactor for BRCA1 was investigated.
RESULTS: We found a physical interaction between the carboxyl terminus of TFII-I and the carboxyl terminus of BRCA1, also known as
the BRCT domain. Endogenous TFII-I and BRCA1 form a complex in nuclei of intact cells and formation of irradiation-induced nuclear
foci was observed. We also showed that the expression of TFII-I stimulates the transcriptional activation function of BRCT by a
transient expression assay. The expression of TFII-I also enhanced the transcriptional activation of the SIRT1 promoter mediated by
full-length BRCA1.
CONCLUSION: These results revealed the intrinsic mechanism that TFII-I may modulate the cellular functions of BRCA1, and provide
important implications to understand the development of breast cancer.
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The TFII-I was identified originally as a factor that could bind to
two distinct promoter elements, the pyrimidine-rich initiator and
the recognition site (E-box) for upstream factor 1. The TFII-I
stimulates transcription from the potent TATA- and initiator-
containing adenovirus major late promoter (AdMLP) synergisti-
cally with upstream factor 1 (Roy et al, 1997). The TFII-I is a
unique multifunctional factor that selectively regulates gene
expressions when activated by a variety of extracellular signals
and can function both as a basal transcriptional factor and as an
activator (Roy, 2007). An autosomal dominant genetic disorder
Williams–Beuren syndrome is a multisystem disorder charac-
terised by distinctive facial features, mental disability, diabetes
mellitus, and supravalvular aortic stenosis. The haploinsufficiency
for TFII-I is causative to the craniofacial phenotype in humans
(Pober, 2010). The primary structure of TFII-I is compatible with
its multifunctional properties, consisting of six direct reiterated
I-repeats, R1–R6, each containing a putative helix-loop-helix
motif (Roy, 2007). The I-repeats are postulated to be protein
interaction surfaces. Given those multifunctional features and
structural characteristics, it is important to investigate the role of
the I-repeats in mediating protein interactions and to search for
proteins that make complex with TFII-I through this domain.
The breast cancer susceptibility gene BRCA1 encodes a
phosphoprotein that is involved in ubiquitination, DNA damage
response, regulation of cell cycle checkpoints, and transcriptional
regulation. Binding to the transcriptional machinery by the
carboxyl terminal BRCA1, referred to as BRCT domain, was
the first biochemical activity ascribed to the BRCA1 protein
(Anderson et al, 1998). In addition, BRCT has been shown to be
involved in double-stranded DNA repair and homologous
recombination (Callebaut and Mornon, 1997; Moynahan et al,
1999; Zhong et al, 1999). On the basis of the data that targeted
deletion of the BRCT domain results in embryonic lethality
(Hohenstein et al, 2001), BRCT is postulated to be indispensable for
the normal cellular growth, and it would be intriguing to investigate
physiological functions of BRCT. BRCA1 carboxyl-terminal domain
(BRCT) possesses the autonomous transcriptional activation
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sfunction when the BRCT domain is fused to a GAL4 DNA-binding
domain (Monteiro et al, 1996). The point mutations in the BRCT
domain derived from patients with inherited breast cancer result in
loss of transcriptional activity (Chapman and Verma, 1996). The
BRCT domain has been shown to be an interaction surface with a
number of transcription factors and co-regulators (Saka et al, 1997;
Wada et al, 2004; Oishi et al, 2006; Hiraike et al,2 0 1 0 ) .
To better understand the functional significance and the
transcriptional regulation of BRCT, we previously have searched
for putative transcription coactivator complexes that interact with
the BRCT domain using a biochemical approach (Wada et al,
2004; Oishi et al, 2006). During these studies, we preliminary
found that TFII-I interacted with the BRCT domain. Here, we
confirmed that the carboxyl terminus of TFII-I and BRCA1 form a
complex in vivo. We further studied the effect on transcriptional
regulation of BRCA1 driven by TFII-I. These findings establish a
principal biological function of TFII-I as an activator of BRCA1
function, and identify TFII-I as a possible determinant of breast
cancer.
MATERIALS AND METHODS
Cell culture
Human cervical adenocarcinoma HeLa (CCL-2), HCC1937 (CRL-
2336) breast cancer cells that express a carboxyl-terminally
truncated BRCA1 protein (Scully et al, 1999), and African green
monkey kidney fibroblast-like COS7 (CRL-1651) cell lines were
purchased from the American Type Culture Collection (Manassas,
VA, USA). HeLa and COS7 cells were maintained in Dulbecco’s
modified Eagle medium supplemented with 10% fetal bovine
serum. HCC1937 cells were maintained in RPMI medium
supplemented with 10% fetal bovine serum.
Plasmid construction
BRCA1 expression vectors, BRCT vectors and reporter constructs
(17M8-AdMLP-luc and SIRT1-luc) were described previously
(Wada et al, 2004; Hiraike et al, 2010). TFII-I expression vectors
were described previously (Cheriyath and Roy, 2001).
Chemicals and antibodies
Rabbit antibodies were anti-TFII-I, anti-BRCA1, and anti-GST
(Cell Signaling Technology Inc., Temecula, CA, USA, catalogue no.
#4562, #9010, and #2622, respectively). Mouse monoclonal
antibodies were anti-BRCA1 (Calbiochem, EMD Biosciences Inc.,
La Jolla, CA, USA, catalogue no. OP107), anti-SIRT1 (Abcam Ltd.,
Cambridge, UK, catalogue no. ab32441), and HRP-conjugated anti-
Flag (Abcam Ltd., catalogue no. ab49763). Anti-BRCA1 (catalogue
no. sc-642), anti-p53 (catalogue no. sc-126), and anti-Actin
(catalogue no. sc-47778) were purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). Alexa Fluor 488
conjugated donkey anti-mouse IgG (catalogue no. A-21202) and
Alexa Fluor 568 conjugated goat anti-rabbit IgG (catalogue no. A-
11011) were purchased from Invitrogen (Carlsbad, CA, USA).
Immunoprecipitation and western blot
The formation of a TFII-I-BRCA1 complex in HeLa, HCC1937, and
COS7 cells was analysed by immunoprecipitation. The whole-cell
extracts of HeLa and HCC1937 cells were applied for immuno-
precipitation with anti-BRCA1 antibodies or preimmune IgG. The
immunoprecipitates were subjected to 30ml of protein G sepharose
4 Fast Flow (GE healthcare UK Ltd., Buckinghamshire, UK) and
subsequently immunoblotted by anti-TFII-I antibodies. Reciprocal
immunoprecipitation was also performed. COS7 cells transfected
with indicated plasmids were lysed, fractionated, and subjected to
anti-FLAG M2 agarose (Sigma-Aldrich, St Louis, MO, USA).
Immunoprecipitated materials were blotted with anti-GST anti-
bodies to identify TFII-I-containing complexes.
RNAi
The ablation of TFII-I and BRCA1 was performed by transfection
of HeLa cells with siRNA duplex oligos synthesised by Qiagen
(Hilden, Germany). Cells were transfected with control siRNA
(AllStars Negative Control siRNA, 1027281), TFII-I-specific siRNA
(TFII-I-RNAi: 50-AAACGGAGCCUACUGAACA-30, which covered
mRNA regions of nucleotides 956–974 (amino acids 195–201) of
TFII-I), DBC1-specific siRNA (DBC1-RNAi: 50-AAACGGAGCCUA
CUGAACA-30, which covered mRNA regions of nucleotides
1379–1397 (amino acids 460–466) of DBC1), and BRCA1-specific
siRNA (SI02664361) using HiperFect reagent (Qiagen).
GST-pull down assay
Glutathione-S-transferase fusion proteins or GST alone were
expressed in Escherichia coli and immobilised on glutathione-
sepharose 4B beads (GE healthcare UK Ltd.). The GST proteins
were incubated with nuclear extracts of HeLa cells. Unbound
proteins were removed and specifically bound proteins were eluted
and analysed by SDS–PAGE.
Luciferase assay
Transfection was performed with Effectene reagent (Qiagen) or
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
recommendation. For luciferase assay, cells were transfected with
indicated expression vectors and/or GAL4 vectors. Reporter
plasmids (17M8-AdMLP-luc or SIRT1-luc) were also cotransfected.
As an internal control to equalise transfection efficiency, phRL
CMV-Renilla vector (Promega Co., Madison, WI, USA) was also
transfected in all the experiments. Individual transfections, each
consisting of triplicate wells, were repeated at least three times as
described previously (Wada et al, 2004).
Fluorescence microscopy
HeLa cells were grown on 12mm BD BioCoat glass coverslips (BD
Biosciences, San Jose, CA, USA, 354085) in 6-well plates. The cells
were exposed to 8-gray (Gy) of g-irradiation, fixed with PBS
containing 4% paraformaldehyde and permeabilised in PBS with
0.2% (v/v) Triton X-100. After blocking, the cells were incubated
sequentially with anti-BRCA1 and anti-TFII-I antibodies.
Secondary antibodies were Alexa Fluor 488 conjugated donkey
anti-mouse IgG, or Alexa Fluor 568 conjugated goat anti-rabbit
IgG. The slides were briefly counter-stained and analysed under
the confocal fluorescence microscope (Carl-Zeiss MicroImaging
Inc., Oberkochen, Germany). Quantification of colocalisation was
analysed using LSM7 series-ZEN200x software (Carl-Zeiss Micro-
Imaging Inc.), and the ratio of colocalisation pixels vs total pixels
in the target area was measured.
Chromatin immunoprecipitation assay
Preparation of soluble HeLa chromatin for PCR amplification was
performed essentially as described (Oishi et al, 2006; Hiraike et al,
2010). Subconfluent HeLa cells were cross-linked with 1.5%
formaldehyde at room temperature for 15min, and washed twice
with ice-cold PBS. The cell pellet was then resuspended in 0.2ml
lysis buffer and sonicated by Bioruptor UCD-250 (Cosmo Bio Co.
Ltd., Tokyo, Japan). The sheared soluble chromatin was then
subjected to immunoprecipitation with specific antibodies and
protein G-sepharose equilibrated with salmon sperm DNA
(Millipore, Upstate, Billerica, MA, USA). After extensive wash,
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sthe beads were eluted. The eluate was incubated for 6h at 651Ct o
reverse the formaldehyde cross-linking. The extracted DNA was
purified with the use of QIAquick PCR purification kit (Qiagen).
Polymerase chain reaction was performed using specific primers
for the SIRT1 promoter (Wang et al, 2008; Hiraike et al, 2010) and
the p21 promoter (Oishi et al, 2006).
RESULTS
TFII-I and BRCA1 interact in vivo
The pull-down products of nuclear extracts from HeLa cells
through GST-BRCT column were separated by SDS–PAGE. In
consistent with our preliminary result, we confirmed that TFII-I
proteins interact with GST-BRCT by western blot (Figure 1A). To
determine the interaction between the endogenous TFII-I and
BRCA1 in cultured human cells, whole-cell lysates of HeLa cells
were immunoprecipitated with anti-BRCA1 antibodies (epitope
mapping at the carboxyl-terminus of BRCA1). The immunoblot-
ting analysis using anti-TFII-I antibodies revealed the existence of
TFII-I in cell lysate immunoprecipitates (Figure 1B, 1), which
indicates that TFII-I physically associates with BRCA1 in living
cells. The whole-cell extracts of HCC1937 cells known to lack last
BRCT domain were also immunoprecipitated with anti-BRCA1
antibodies (epitope mapping at the amino-terminus of BRCA1).
The immunoblotting analysis revealed the absence of TFII-I in cell
lysate immunoprecipitates, which reinforced the importance of
BRCT domain as the interaction surface with TFII-I (Figure 1B, 2).
These data indicated that TFII-I interacted with BRCA1 through
the BRCT domain. Reciprocal immunoprecipitation analysis
confirmed this association (Figure 1B, 3).
To identify the regions of TFII-I that are responsible for the
interaction with BRCT, deletion mutants of TFII-I were used for
the assay. COS7 cells were transfected with Flag-tagged BRCA1 and
GST-tagged TFII-I and nuclear extracts of transfected cells were
immunoprecipitated with the anti-FLAG M2 agarose beads.
Western blotting analysis with anti-GST antibodies revealed the
existence of GST-tagged TFII-I in the protein extract of
immunoprecipitates (Figure 1C), confirming that BRCA1 forms a
complex with TFII-I. Flag-tagged BRCA1 and deletion mutants of
GST-tagged TFII-I were also subjected to immunoprecipitation.
TFII-I lacking the amino terminal region (TFII-I DN90) also
interacted with BRCA1, while TFII-I lacking carboxyl terminus
(TFII-I p70 and p46) showed no interaction with BRCA1.
Immunoprecipitation using cytoplasmic fraction of the COS7 cells
was also performed and TFII-I was not co-immunoprecipitated
with BRCA1. These findings indicate that the carboxyl terminus
(R3-R6) of TFII-I and the BRCT domain are both necessary and
sufficient for the interaction between TFII-I and BRCA1 in
cultured cells.
TFII-I and BRCA1 form endogenous complex in intact cells
and nuclear foci in DNA-damaged cells
As BRCA1 and TFII-I interact in vivo, it was of interest to examine
the subcellular distribution of these two proteins. To this end,
immunofluorescence analysis was performed on HeLa cells. More
than 80% substantial colocalisation signal (Merge) of BRCA1
(Alexa Fluor 488-conjugated anti-mouse IgG, green) and TFII-I
(Alexa Fluor 568-conjugated anti-rabbit IgG, red) was observed in
nuclei in control cells. Therefore, protein complexes containing
both BRCA1 and TFII-I are likely to be distributed throughout
nuclei. This result also implied the importance of nuclear
localisation signal for the colocalisation of BRCA1 and TFII-I in
nuclei. The previous study demonstrated that BRCA1 has been
shown to display discrete nuclear foci after treatment of cells with
irradiation (Zhong et al, 1999). HeLa cells irradiated with 8-Gy
g radiation demonstrated the punctate pattern of immunostaining
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Figure 1 In vivo and in vitro association between TFII-I and BRCA1, and mapping of the BRCT-interacting region of TFII-I. (A) Identification of the
interaction between BRCT and TFII-I using GST-BRCT. Bacterially expressed GST fusion proteins immobilised on beads were used in in vitro pull-down
assays. Nuclear extracts of HeLa cells were incubated with GST-BRCT. The beads were extensively washed, and followed by immunoblotting (IB) using anti-
TFII-I antibodies. (B) The complex formation of TFII-I and BRCA1 in HeLa cells was analysed by co-immunoprecipitation (IP) with the antibodies to BRCA1
(epitope mapping at the carboxyl-terminus of BRCA1). The immunoblotting analysis using anti-TFII-I antibodies revealed the existence of TFII-I in cell lysate
immunoprecipitates (Figure 1B, 1), which indicates that TFII-I physically associates with BRCA1 in living cells. Reciprocal immunoprecipitation analysis
confirmed the association of TFII-I and BRCA1 (Figure 1B, 3). The whole-cell extracts of HCC1937 cells known to lack last BRCT domain were also
immunoprecipitated with anti-BRCA1 antibodies (epitope mapping at the amino-terminus of BRCA1). The immunoblotting analysis revealed the absenceo f
TFII-I in cell lysate immunoprecipitates (Figure 1B, 2), indicating the importance of BRCT as a binding surface of TFII-I. (C) Mapping of the BRCT-interaction
region of TFII-I. COS7 cells were transfected with GST-tagged TFII-I (wild type, DN90, p70, and p46) and Flag-tagged BRCA1 expression vectors. Nuclear
extracts of transfected COS7 cells were prepared and the complex formation of TFII-I and BRCA1 was analysed by IP with the anti-Flag M2 agarose beads,
followed by IB using anti-GST antibodies. (D) A schematic diagram of the structure of TFII-I (wild type, DN90, p70, p46, and b isoform) is shown.
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cells (Figure 2B, 1–3). These data indicated that double strand
DNA damage lead to the nuclear accumulation of the BRCA1-TFII-I
complex, possibly at the site of double strand DNA-damage.
TFII-I enhances the transcriptional activation of BRCT
The result that the BRCT domain interacts with TFII-I led us to
examine role of TFII-I in the transactivation function of GAL4-
fused BRCT. Transient transfection assays were performed using a
17M8-AdMLP-luc luciferase reporter plasmid, carrying eight
tandem repeat GAL4 DNA-binding sites (17M 8) upstream of
AdMLP driving expression of the firefly luciferase gene. The TFII-I
alone had no effect on this luciferase reporter construct (Figure 3,
lanes 2–6). Although GAL4-BRCT fusion protein (GAL-BRCT)
activated the promoter activity of the reporter plasmid in COS7
cells, the transcriptional activity of BRCT was significantly
stimulated by the expression of TFII-I at best two-fold on the
artificial promoter in luciferase assays (Figure 3, lanes 7–8).
Although TFII-I DN90 possessing the BRCT binding domain
stimulated the transcriptional activation of GAL-BRCT, TFII-I
lacking an interaction domain with BRCA1 (TFII-I p70 and p46)
lost its ability to stimulate the BRCT-mediated transcriptional
activation (Figure 3, lanes 9–11). The mammalian TFII-I has four
spliced isoforms: a, b, g, and D (wild type). Upon serum starvation,
the b and D isoforms exhibits subcellular distribution changes in
murine NIH3T3 cells (Hakre et al, 2006). The experimental data
showed that TFII-I b also stimulated the transcriptional activation
of BRCT (Figure 3, lane 12). These results suggest that carboxyl
terminus of TFII-I has a significant role in the stimulation of
BRCT-dependent transactivation.
10 m 10 m1 0   m1 0   m1 0   m
10 m 10 m 10 m 10 m
10 m1 0   m1 0   m1 0   m
10 m 10 m 10 m 10 m
Figure 2 Colocalisation of BRCA1 and TFII-I in HeLa cells. (A–D) HeLa cells were either treated by 8-Gy of gamma-irradiation or none, fixed, and
permeabilised. The cells were incubated with primary antibodies and subsequently with secondary antibodies. The expression of BRCA1 (green) and TFII-I
(red) was investigated under the confocal fluorescence microscopy (Carl-Zeiss). Representative immunofluorescence studies are shown (A, control cells;
B, irradiated cells; 1, TFII-I; 2, BRCA1; 3, merge; 4, 40, 6-diamino-2-phenylindole staining). Arrows in B3 indicate a cell showing nuclear foci formation of TFII-I
and BRCA1. Bars indicate 10mm.
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The previous chromatin immunoprecipitation assay showed that
BRCA1 interacted with the SIRT1 promoter region between 1354
and 1902 and this binding resulted in elevated expression of SIRT1
(Wang et al, 2008; Hiraike et al, 2010). We explored whether
TFII-I has an effect on the BRCA1-mediated stimulation of the
SIRT1 promoter and demonstrated that the BRCA1-mediated
stimulation of the SIRT1 promoter was specifically upregulated by
exogenous expression of TFII-I although the impact of TFII-I was
rather less on SIRT1 promoter compared with AdMLP (Figure 4A,
lane 8). The TFII-I p70 and p46 showed no influence to enhance
the BRCA1-mediated transactivation of SIRT1-luciferase reporter
constructs, but TFII-I DN90 showed enhancement on the SIRT1-
luciferase transactivation function mediated by BRCA1 (Figure 4,
lanes 9–11). The TFII-I b was also able to stimulate the SIRT1-
luciferase transcriptional activation function mediated by BRCA1
(Figure 4, lane 12). Interaction of BRCA1 with the SIRT1 promoter
region was postulated to be important for the activation function
of TFII-I because SIRT1-luciferase (1–202) reporter constructs
lacking the BRCA1-interaction site showed no enhancement of
luciferase activity.
We next examined the effect of siRNA-mediated depletion of
TFII-I or BRCA1 on their downstream genes. Knockdown of
BRCA1 expression by BRCA1-specific siRNA abrogated the
expression of SIRT1 (Figure 4B, lane 3), validating the previous
report that the expression of SIRT1 is indeed dependent on BRCA1
(Wang et al, 2008). As shown in Figure 4B, lane 2, depletion of the
endogenous TFII-I also decreased the expression of SIRT1. Thus,
our data demonstrate that TFII-I has a critical role in regulating
downstream gene expressions dependent on BRCA1 in vivo.
Depletion of TFII-I resulted in downregulation of p53 and BRCA1,
suggesting a role of TFII-I in DNA damage response (Figure 4B,
lane 2).
To test whether TFII-I and BRCA1 were indeed recruited to the
SIRT1 promoter, we performed a chromatin immunoprecipitation
assay using the SIRT1 gene promoter 1354–1902, a region known
to recruit BRCA1 (Wang et al, 2008; Hiraike et al, 2010) and the
p21 gene promoter (Oishi et al, 2006). As expected, clear
recruitment of endogenous TFII-I and BRCA1 to the target
sequence (1354–1902) in the SIRT1 and the p21 promoter was
observed in HeLa cells (Figure 4C).
DISCUSSION
The TFII-I is considered to have important roles in regulating the
expression of genes as a signal-induced multifunctional transcrip-
tion factor (Hakre et al, 2006; Roy, 2007). Here, we demonstrated
that endogenous TFII-I associated with BRCA1, which suggests the
possibility that TFII-I has a functional relationship with BRCA1-
related phenotypical changes. This interaction between BRCA1 and
TFII-I was physiologically functional because our results demon-
strated that the TFII-I-containing complex stimulated the auton-
omous transcriptional activity of BRCT.
The transcriptional activation function of BRCT is considered to
be a key to its tumour suppressor activity (Chapman and Verma,
1996; Monteiro et al, 1996) because a point mutation within the
BRCT domain (A1708E), lacking transactivation function, was
shown to be critical for a DNA damage response by the treatment
with methylmethane sulfonate (Zhong et al, 1999). The importance
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Figure 3 TFII-I stimulates transcription of GAL4-BRCT through its
carboxyl-terminal domain. Transient transfection assays were performed to
examine the cofactor activity of TFII-I in the transactivation function of
GAL4-fused BRCT. COS7 cells were transfected with the indicated
combinations of mammalian expression plasmids. At 24h after transfection,
the cells were harvested, and transfected whole-cell lysates were assayed
for luciferase activity produced from the reporter plasmid (17M8-AdMLP-
luc). TFII-I showed a specific stimulation of the transactivation function of
BRCT. Carboxyl-terminus of TFII-I was indispensable for this stimulation
of BRCT. The phRL Renilla CMV-luc vector was transfected as a control of
transfection efficiency. Each experiment was repeated at least three times
in triplicate. Error bars represent s.d.
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Figure 4 TFII-I stimulates transcription by BRCA1 through its carboxyl-
terminal domain. (A) Transient transfection assays were performed to
examine the influence of TFII-I using an artificial luciferase reporter
constructs. COS7 cells were transfected with the indicated combinations of
mammalian expression plasmids. At 24h after transfection, cells were
harvested, and transfected whole-cell lysates were assayed for luciferase
activity produced from the reporter plasmids. Full-length TFII-I and TFII-I
DN90 showed specific upregulation of SIRT1 (1-2852)-luciferase activity
mediated by BRCA1, while TFII-I p70 and TFII-I p46, lacking BRCT-
interaction region, had no effect on SIRT1-luciferase activity. TFII-I showed
no effect on SIRT1 (1-202)-luciferase activity that lack the binding domain
of BRCA1. (B) The siRNA-mediated knockdown of BRCA1 decreased the
expression of SIRT1. Knockdown of TFII-I also resulted in downregulation
of SIRT1. Expression of BRCA1 and p53 was decreased by depletion of
TFII-I. HeLa cells were transfected with indicated siRNA. At 48h after
transfection, cells were harvested and analysed by western blotting.
(C) Chromatin immunoprecipitation assay was performed to confirm the
recruitment of BRCA1 and TFII-I at the SIRT1 gene promoter and the p21
gene promoter. Both promoter regions are known to recruit BRCA1.
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highlighted by the fact that cancer associated mutations attenuated
both, but neutral polymorphism did not (Humphrey et al, 1997).
The BRCT domain is found in a diverse group of proteins
implicated in DNA repair and cell cycle check-point control (Bork
et al, 1997; Callebaut and Mornon, 1997). BRCA1 carboxyl-
terminal domain possesses an autonomous folding unit defined by
conserved clusters of hydrophobic amino acids, and BRCT is likely
to represent a protein interaction surface (Saka et al, 1997). Thus,
activation of BRCT has implications both in anti-tumorigenic and
in DNA repair processes. Anti-tumorigenic role of TFII-I is also
supported by the finding that TFII-I inhibits the growth of MCF-7
(Ogura et al, 2006). The study had shown that TFII-I down-
regulates a subset of oestrogen-responsive genes, only those
containing initiator elements, by recruiting oestrogen receptor a
and co-repressors to these promoters. Therefore, TFII-I is not
thought to be a general activator of transcription and the
transcriptional control by TFII-I would be promoter-dependent
manner. The transcriptional regulation played by TFII-I may be
complicated because TFII-I was shown to co-immunoprecipitates
with transcriptional repressor, histone deacetylase 3 (Wen et al,
2003).
We also have shown that TFII-I and BRCA1 colocalise in nuclei
of irradiated cells. Previous studies indicated that BRCA1 responds
to the repair of DNA by homologous recombination. The BRCA1
associates with RAD51 in subnuclear clusters (Zhong et al, 1999).
The RAD51 is postulated to be a key component of the mechanism
in which DNA damage is repaired by homologous recombination.
When cells are exposed to ionising radiation, both BRCA1 and
RAD51 localise to the damaged region, and both BRCA1 and
RAD51 initiate homologous recombination and the repair of
double-strand breaks. Our data that TFII-I and BRCA1 formed
nuclear foci after irradiation treatment may suggest that both
BRCA1 and TFII-I participates in the DNA damage repair pathway.
These data are consistent with the previous observation that TFII-I
influences persistence of g-H2AX foci and thus affects double
strand break repair, suggesting a role for TFII-I in DNA repair
(Desgranges and Roy, 2006). Our results also indicated that TFII-I
promoted BRCA1-dependent transcriptional regulation because
SIRT1-luciferase activity was potentiated by the ectopic expression
of TFII-I. The TFII-I would serve as a transcriptional activation
factor to manipulate transcriptions, thereby influencing transcrip-
tional products such as SIRT1. These results also suggest the
possible mechanism how TFII-I regulates DNA damage machinery
because SIRT1 possesses DNA repair activity (Jeong et al, 2007). In
consistent with these data, depletion of endogenous TFII-I resulted
in a decreased expression of p53 and BRCA1. We have to further
confirm the effect of DNA damage response when TFII-I is
abrogated to show its involvement in this mechanism. Our results
showed a new insight that TFII-I may serve, at least in part, as
DNA damage response machinery.
In conclusion, our data indicate that TFII-I have an important
role in regulating BRCA1-mediated functions through binding to
the BRCT domain and it may be probable that TFII-I is involved in
anti-tumorigenic processes. The meaning of TFII-I functions
would be apparent by evaluating its expression in tumour tissues
such as breast cancer. The expression of TFII-I would be
therapeutically beneficial by affecting different TFII-I-mediated
regulatory pathways together with BRCA1 and the failure of
binding between BRCA1 and TFII-I may be a key event in cancer
predisposition.
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